Rigel Pharmaceuticals Inc (FRA:RI2)
€ 33.87 -0.66 (-1.91%) Market Cap: 651.15 Mil Enterprise Value: 603.10 Mil PE Ratio: 2.35 PB Ratio: 1.69 GF Score: 24/100

Q1 2026 Rigel Pharmaceuticals Inc Earnings Call Transcript

May 05, 2026 / 08:30PM GMT
Release Date Price: €24.85 (-0.48%)
Operator

Greetings and welcome to Rigel Pharmaceuticals' financial conference call for the first quarter 2026.

(Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce our speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you. Mr. Furey, you may begin.

Raymond Furey
Rigel Pharmaceuticals Inc - Executive Vice President, General Counsel, and Corporate Secretary

Welcome to our first quarter 2026 financial results business update conference call. The financial press release for the first quarter 2026 was issued a short while ago and can be viewed along with the slides for this presentation in the News and Events section of our Investor Relations site on rigel.com.

As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot